Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children
NCT: NCT06929702 · RECRUITING
Brief Summary
The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem) in critically ill children. This evaluation includes a comparison with the more standard approach on clinical and patient-oriented measures.
Frequently Asked Questions
What is Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children?
Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children is a clinical trial registered under NCT06929702. Current status: RECRUITING.
What is the status of NCT06929702?
The current status of NCT06929702 (Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children) is: RECRUITING.
When did Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children start?
Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children started on 2025-07-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.